1. Introduction {#sec0005}
===============

The incidence of breast cancer in Korea is increasing, and the incidence of estrogen receptor (ER) positive breast cancer increased from 58.2% in 2002 to 73.7% in 2015 \[[@bib0005]\]. Tamoxifen is a selective estrogen receptor modulator that can be used to increase the treatment effect in hormone receptor (HR) positive breast cancer diagnosed prior to menopause and metastatic or recurrent HR positive breast cancer \[[@bib0005]\]. Various side effects of tamoxifen such as weight gain, sexual dysfunction, hot flashes, neurocognitive deficits, thrombogenic events, and ocular events have been reported \[[@bib0010]\]. However, tamoxifen-induced pneumonia is a very rare side effect \[[@bib0015]\].

Herein, we present a case of acute eosinophilic pneumonia after tamoxifen administration in a patient with ER positive breast cancer patient who underwent mastectomy. This work is reported in line with the SCARE criteria \[[@bib0065]\].

2. Presentation of case {#sec0010}
=======================

A 46-year-old female patient presented to our outpatient clinic for further evaluation of a mass in the left breast that was detected incidentally at a routine health screen in February 2018. She was transferred from the intensive care unit at another center where she was admitted for the treatment of exacerbated epilepsy. Anamnesis revealed a history of mental retardation and medication for epilepsy, but no history of allergy, smoking, and surgery; family history indicated that her sister had received treatment for breast cancer. Ultrasound-guided core needle biopsy performed at our center confirmed a diagnosis of invasive ductal carcinoma. Positron emission tomography--computed tomography and breast ultrasound showed the absence of axillary lymph node involvement, and breast magnetic resonance imaging could not be performed due to the patient's lack of cooperation. Skin-sparing mastectomy and reconstruction with silicone was performed on April 11, 2018. Histology indicated invasive ductal carcinoma with a mass of 26 × 15 × 15 mm and metastasis in 9 of 10 axillary lymph nodes. The cancer stage was IIIA with T2N2aM0, with ER 8(5 + 3), PR 8(5 + 3), c-erbB2(1+/3), and KI-67(10%).

Treatment with tamoxifen (20 mg/daily) was started on post-operative day 14. On post-operative day 16 (day 3 of tamoxifen treatment), she showed no symptoms other than fever of 39.1 °C. The results of investigation to determine the cause of fever were normal (WBC 6.6 × 10^3^/uL, eosinophil 0.6%) except for mild elevation in the C-reactive protein (CRP) level of 1.13 mg/dL. Culture test for wound infection, using 7 mL of fluid obtained under ultrasound guidance was negative.

Since wound infection could not be completely ruled out as a cause of fever, rifampin (150 mg twice daily) was administered. However, there was persistence of fever of above 39 °C on post-operative day 19 (day 6 of tamoxifen treatment), and absence of redness or pain at the wound site. To rule out antibiotic-related fever, the antibiotic regimen was switched to combined piperacillin and tazobactam, and vancomycin.

On post-operative day 20 (day 7 of tamoxifen treatment), the patient had cough with profuse sputum production and fever of 40.5 °C. Chest radiograph showed soft haziness at the right middle lung field and blunting of the costophrenic angle with subsegmental atelectasis at the left lower lung field \[[Fig. 1](#fig0005){ref-type="fig"}\]. Complete blood count showed a marked increase in the level of eosinophils from 0.2% on day 5 to 3.7% on day 7 of tamoxifen treatment, but WBC was not elevated at 4.8 × 10^3^/uL and the CRP level was increased to 7.94 mg/dL.Fig. 1Chest x-ray on post-operative Day 20. Soft haziness in the right middle lung field and costophrenic angle blunting with subsegmental atelectasis in left lower lung field are observed.Fig. 1

On postoperative day 21(day 8 of tamoxifen treatment), chest computed tomography(CT) was performed, which showed ground glass opacity, interlobular septal thickening, and mild pleural effusion in both lungs. Based on these findings, the patient was diagnosed with suspicious eosinophilic pneumonia \[[Fig. 2](#fig0010){ref-type="fig"}\]. She complained of severe dyspnea and showed unstable oxygen saturation of 88% and was transferred to the intensive care unit for close monitoring. The laboratory investigations at the time showed WBC 5.2 × 10^3^/uL, eosinophil 3.6%, and a further increase in CRP level to 8.63 mg/dL. Concomitant blood culture was negative.Fig. 2Chest CT on post-operative Day 21. Ground-glass opacification and interlobular septal thickening, and mild pleural effusion in both lungs.Fig. 2

Tamoxifen, administered from post-operative day 14, was considered as the probable cause of eosinophilic pneumonia, and discontinued on post-operative day 21 after chest CT was performed. Methylprednisolone (30 mg twice daily) was administered intravenously and tapered by 10 mg every 3 days. Oral methylprednisolone (24 mg daily) was started from post-operative day 29, and reduced dose of the drug (12 mg daily) was administered from post-operative day 33. After the discontinuation of tamoxifen, there was less fever and recovery to normal temperature at day 3 post-discontinuation of tamoxifen. Oxygen saturation was recovered to normal level, and dyspnea was improved. Chest radiographs acquired daily after discontinuation of tamoxifen showed a decrease in haziness, and sputum and cough were reduced.

Mycoplasma pneumonia immunoglobulin M (IgM), *Chlamydia pneumonia* IgM, pneumonia urinary antigen, Gram stain, and polymerase chain reaction for *Mycoplasma tuberculosis* performed in the intensive care unit on post-operative day 22 demonstrated negative results. On postoperative day 33 (day 12 post-discontinuation of tamoxifen), the patient showed improvement of symptoms and was discharged.

3. Discussion {#sec0015}
=============

Eosinophilic lung disease refers to a condition with an increase in eosinophil count in the peripheral blood or lung tissue \[[@bib0020], [@bib0025], [@bib0030]\]. Allen and Davis classified eosinophilic pneumonia as an increase in eosinophils in the peripheral blood accompanied by lung infiltration on chest radiography, or eosinophil infiltration through lung histology without an increase in eosinophils in the peripheral blood, or alveolar lavage fluid \[[@bib0020],[@bib0025]\]. Eosinophilic lung diseases include simple pulmonary eosinophilia, chronic eosinophilic pneumonia, acute eosinophilic pneumonia, idiopathic hypereosinophilic syndrome, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis, parasites, and drugs \[[@bib0020],[@bib0025]\]. Acute eosinophilic pneumonia can be defined as fever and respiratory distress with myalgia, chest pain, and hypoxia of 1--5 days' duration that completely resolve without recurrence spontaneously or after the administration of an adrenal cortex hormone in patient without underlying respiratory disease \[[@bib0020],[@bib0025]\].

Acute eosinophilic pneumonia shows the following test results: minute interstitial lung infiltration on the chest radiograph that progresses rapidly within 2 days to mixed alveolar and interstitial infiltration, bilateral ground glass opacity and diffuse, reticular densities on CT \[[@bib0030],[@bib0035]\]. Acute eosinophilic pneumonia can be caused by drugs. Drugs known to cause acute eosinophilic pneumonia are listed in [Table 1](#tbl0005){ref-type="table"} \[[@bib0025],[@bib0030]\].Table 1Drugs causing eosinophilic lung disease.Table 1AmpicillinMethylphenidateBeclomethasone dipropionateMinocyclineBleomycinNaproxenCarbamazepineNickelChlorpromazineNitrofurantoinClofibratePara-aminosalicylic acidCocaine(inhaled)PenicillinCromolyn(inhaled)Pentamidine(inhaled)DesipraminePhenytoinDiclofenacPyrimethamineFebarbamateRapeseed oilGlafenineSulfadimethoximeGM-CSFSulfasalazineIbuprofenSulindacInterleukin 2&3TamoxifenIodinated contrast mediaTetracycline[l]{.smallcaps}-TryptophanTolazamideMephenesin carbamateTolfenamic acidMethotrexateVaginal sulfonamide creamAdapted from Allen and Davis \[[@bib0025]\].

Tamoxifen, often used as antihormonal therapy in the treatment of breast cancer, can cause various side effects such as weight gain, sexual dysfunction/loss of libido, hot flashes, neurocognitive deficits, thromboembolic events, ocular events, mood alterations, depression, GI disturbance, bone pain, leg cramps, and insomnia \[[@bib0010]\]. Pneumonia is a rare side effect of tamoxifen and there are only a few reports of pneumonia in patients who were started on tamoxifen after surgery for breast cancer \[[@bib0035], [@bib0040], [@bib0045], [@bib0050], [@bib0055]\].

In our case, tamoxifen was considered as the cause of eosinophilic pneumonia due to the association between fever onset and time of first tamoxifen administration. The patient developed high-grade fever of over 39 °C from day 3 of tamoxifen administration, which subsided after the discontinuation of tamoxifen \[[Fig. 3](#fig0015){ref-type="fig"}\].Fig. 3Patient's body temperature and eosinophil count by tamoxifen administration.Fig. 3

To confirm tamoxifen as the cause of a patient's pneumonia, tamoxifen should be restarted under patient monitoring for pneumonia recurrence as described in Etori et al. \[[@bib0015]\]. Previous case reports of tamoxifen-induced pneumonia according to the symptoms, symptom onset-time from medication, and restarting or not are summarized in [Table 2](#tbl0010){ref-type="table"}.Table 2Side effects of tamoxifen-induced pneumonia in previous case report.Table 2Symptom onset at post-medication time pointSymptomsRestartingSymptoms after restartingAhmed et al. \[[@bib0050]\]1weekCoughNoNot reporteddyspneaintermittent fevermechanical ventilationShiiki et al. \[[@bib0060]\]2dayCoughYesCoughdyspneadyspneaEtori et al. \[[@bib0015]\]3monthMild coughYesCoughdyspnea on exertionKwon et al.[a](#tblfn0005){ref-type="table-fn"}3dayCoughYesItching sensedyspneaFever (40.5 °C)[^1][^2]

In this case, the patient was restarted on tamoxifen 20 mg once daily from May 28, 2018 to confirm tamoxifen as the cause of pneumonia and as choice treatment based on the patient's age, histology, and pre-menopausal status. Since the patient experienced tamoxifen-related adverse events, alternative therapy with an aromatase inhibitor was considered. Unlike tamoxifen, aromatase inhibitors are only administered after menopause, hence bilateral salpingooophorectomy(BSO) was required in our patient to induce menopause. The option of BSO and aromatase inhibitor was discussed with the patient's caregiver, and declined based on the concern that the patient's mental status would prevent her from accepting the consequences of surgery and increase her feelings of loss. Concurrent silicone implantation performed at the time of mastectomy was also due to the caregiver's concern for the patient's feeling of loss, though the patient was foreseen to require radiotherapy due to suspicion of axillary lymph node metastasis. However, since the time to natural menopause was too long in our patient, she was administered tamoxifen with methylprednisolone (4 mg twice daily) from May 18, 2018. However, after 1 months' treatment, regular administration was not possible due to the patients' symptom of itching and lack of cooperation.

4. Conclusion {#sec0020}
=============

The current study highlights that in patients undergoing treatment with tamoxifen, if there is development of high-grade fever at 2--3 days after first administration and chest CT shows ground-glass opacification, interlobular septal thickening, and mild pleural effusion, eosinophilic pneumonia due to tamoxifen should be suspected, and tamoxifen should be discontinued. Discontinuation of tamoxifen alone may improve the patient's symptoms. However, for patients with advanced symptoms, steroid therapy may help to alleviate the symptoms.
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[^1]: All cases had initial and restarting dose of tamoxifen of 20 mg daily.

[^2]: Current study.
